Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
316
datasets available to search
ShareScore release 0.9.0
Dataset results
316 results for “Drug Target”
Personalized Targeted Glioblastoma Therapies by ex Vivo Drug Screening
ClinicalTrials.gov study NCT06512311. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Targeted Extinction of Drug Cues During Sleep - Olfactory Cue Reactivity Task
ClinicalTrials.gov study NCT05189379. IPD Sharing: NO. Countries: 1. Publications: 6.
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
ClinicalTrials.gov study NCT02693535. IPD Sharing: Not stated. Countries: 1. Publications: 20.
A Window-of-opportunity Study of U3-1402, a HER3-targeting Antibody-drug Conjugate in Operable Breast Cancer According to ERBB3 Expression
ClinicalTrials.gov study NCT04610528. IPD Sharing: NO. Countries: 1. Publications: 1.
Therapeutic Drug Monitoring - Targeting IMproved Effectiveness
ClinicalTrials.gov study NCT05971979. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.
Immune Checkpoint Inhibitor Monotherapy or Combined With Molecular Targeted Drugs / Locoregional Therapy in the Treatment of Hepatocellular Carcinoma
ClinicalTrials.gov study NCT05609695. IPD Sharing: NO. Countries: 1. Publications: 2.
Discovering Patterns in the Gut Microbiota Associated With the Risk of Stroke and the Outcome After a Stroke and Integration of These Data With Genomic Information to Find New Drug Targets and New Tre
ClinicalTrials.gov study NCT04795687. IPD Sharing: YES. Countries: 1. Publications: 1.
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
ClinicalTrials.gov study NCT03866382. IPD Sharing: YES. Countries: 2. Publications: 1.
Targeting High Risk Populations With Enhanced Reactive Focal Mass Drug Administration in Thailand
ClinicalTrials.gov study NCT05052502. IPD Sharing: NO. Countries: 1. Publications: 15.
SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients
ClinicalTrials.gov study NCT02117167. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.
A Targeted and Tailored Pharmacist Intervention to Improve Adherence to Antihypertensive Drugs Among Diabetes Patients
ClinicalTrials.gov study NCT04023734. IPD Sharing: NO. Countries: 1. Publications: 7.
Optimizing Evidence-based HIV Prevention Targeting People Who Inject Drugs on PrEP
ClinicalTrials.gov study NCT05669534. IPD Sharing: YES. Countries: 1. Publications: 1.
Evaluation of Targeted Mass Drug Administration for Malaria in Ethiopia
ClinicalTrials.gov study NCT04241705. IPD Sharing: NO. Countries: 1. Publications: 1.
cTBS Targeting Cerebellum for Drug-refractory Epilepsy
ClinicalTrials.gov study NCT05042726. IPD Sharing: NO. Countries: 1. Publications: 10.
Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
ClinicalTrials.gov study NCT00340522. IPD Sharing: Not stated. Countries: 1. Publications: 3.
Uncovering Potential Breast Cancer Biomarkers Amp; Possible Drug Targets Using Advanced Quantitative Mass Spectrometry
ClinicalTrials.gov study NCT01619514. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALL
ClinicalTrials.gov study NCT06387121. IPD Sharing: NO. Countries: 1. Publications: 7.
Targeted Drug Combined With CHOP in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma
ClinicalTrials.gov study NCT04480099. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Data from: Numerical simulations of targeted delivery of magnetic drug aerosols in the human upper and central respiratory system: a validation study
In the present study, we investigate the concept of the targeted delivery of pharmaceutical drug aerosols in an anatomically realistic geometry of the human upper and central respiratory system. The geometry considered extends from the mouth inlet to the 8th generation of the bronchial bifurcations and is identical to the phantom model used in the experimental studies of [Banko {em et al.} (2015), Exp. Fluids, {bf 56} (117):1-12]. In our computer simulations, we combine the transitional Reynolds-Averaged Navier-Stokes (RANS) and the wall-resolved Large Eddy Simulation (LES) methods for the air phase with the Lagrangian approach for the particulate (aerosol) phase. We validated simulations against recently obtained magnetic resonance velocimetry (MRV) measurements of [Banko {em et al.} (2015), Exp. Fluids, {bf 56} (117):1-12] that provide full a 3D mean velocity field for steady inspiratory conditions. Both approaches produced good agreement with experiments, and the transitional RANS approach is selected for the multi-phase simulations of aerosols transport, because of significantly lower computational costs. The local and total deposition efficiency are calculated for different classes of pharmaceutical particles (in the $0.1mu$m$le d_{rm p} le 10mu$m range) without and with a paramagnetic core (the shell-core particles). For the latter, an external magnetic field is imposed. The source of the imposed magnetic field was placed in the proximity of the first bronchial bifurcation. We demonstrated that both total- and local-depositions of aerosols at targeted locations can be significantly increased by an applied magnetization force. This finding confirms the possible potential for further advancement of the magnetic drug targeting (MDT) technique for more efficient treatments for respiratory diseases.
Data from: Development and evaluation of a fluorescent antibody-drug conjugate for molecular imaging and targeted therapy of pancreatic cancer
Antibodies are widely available and cost-effective research tools in life science, and antibody conjugates are now extensively used for targeted therapy, immunohistochemical staining, or in vivo diagnostic imaging of cancer. Significant advances in site-specific antibody labeling technologies have enabled the production of highly characterized and homogenous conjugates for biomedical purposes, and some recent studies have utilized site-specific labeling to synthesize bifunctional antibody conjugates with both imaging and drug delivery properties. While these advances are important for the clinical safety and efficacy of such biologics, these techniques can also be difficult, expensive, and time-consuming. Furthermore, antibody-drug conjugates (ADCs) used for tumor treatment generally remain distinct from conjugates used for diagnosis. Thus, there exists a need to develop simple dual-labeling methods for efficient therapeutic and diagnostic evaluation of antibody conjugates in pre-clinical model systems. Here, we present a rapid and simple method utilizing commercially available reagents for synthesizing a dual-labeled fluorescent ADC. Further, we demonstrate the fluorescent ADC's utility for simultaneous targeted therapy and molecular imaging of cancer both in vitro and in vivo. Employing non-site-specific, amine-reactive chemistry, our novel biopharmaceutical theranostic is a monoclonal antibody specific for a carcinoembryonic antigen (CEA) biomarker conjugated to both paclitaxel and a near-infrared (NIR), polyethylene glycol modified (PEGylated) fluorophore (DyLight™ 680-4xPEG). Using in vitro systems, we demonstrate that this fluorescent ADC selectively binds a CEA-positive pancreatic cancer cell line (BxPC-3) in immunofluorescent staining and flow cytometry, exhibits efficient internalization kinetics, and is cytotoxic. Model studies using a xenograft of BxPC-3 cells in athymic mice also show the fluorescent ADC's efficacy in detecting tumors in vivo and inhibiting tumor growth more effectively than equimolar amounts of unconjugated drug. Overall, our results demonstrate that non-selective, amine-targeting chemistry is an effective dual-labeling method for synthesizing and evaluating a bifunctional fluorescent antibody-drug conjugate, allowing concurrent detection, monitoring and treatment of cancer.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.